These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1026071)

  • 41. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
    Balogh F; Romics I
    Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Progestational agents and bone metastasis in breast cancer].
    Leriche N; Bonneterre J
    Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
    Goss PE; Ashley S; Powles TJ; Coombes RC
    Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [High doses of MAP in the treatment of prostatic carcinoma in stage T3-T4. Four-year study].
    Laudi M; De Zan A; De Luca G; Pigato M; Pagliano G
    Minerva Urol; 1982; 34(3):171-6. PubMed ID: 7177068
    [No Abstract]   [Full Text] [Related]  

  • 45. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate].
    Nogueira March JL; Ojea A; Jamardo D; Díez E; Figueiredo L
    Arch Esp Urol; 1985; 38(1):28-34. PubMed ID: 4039554
    [No Abstract]   [Full Text] [Related]  

  • 46. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy.
    De Sy WA; De Wilde P; De Meyer JM; Casselman J; Desmet R; Renders G; Schelfhout W
    Acta Urol Belg; 1988; 56(4):581-8. PubMed ID: 2974680
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase II trial of AMSA in prostatic cancer.
    Natale RB; Yagofa A; Watson RC
    Cancer Treat Rep; 1982 Jan; 66(1):208-9. PubMed ID: 6895482
    [No Abstract]   [Full Text] [Related]  

  • 48. [Treatment of advanced cancer of the breast with synhetic progestational hormones].
    Dogliotti GC; Gavosto F; Molinatti GM
    Minerva Med; 1968 Oct; 59(81):4283-96. PubMed ID: 5686148
    [No Abstract]   [Full Text] [Related]  

  • 49. [Bilateral breast cancer as a complication of a prostatic cancer, treated with hormones].
    Lindberg J; Tallgren U
    Lakartidningen; 1969 Sep; 66(37):3674-8. PubMed ID: 5378939
    [No Abstract]   [Full Text] [Related]  

  • 50. [Estrogen therapy of prostatic cancer. 76 cases of previously undiagnosed prostatic cancer treated with F6066 (bis-(p-acetoxyphenyl)cyclohexylidenemethane) and diethylstilbestrol--a double-blind study].
    Carstensen HE; Olsen CE; Sele V; Brorson I; Jensen E; Nissen NI; Fabricius J
    Nord Med; 1969 Jan; 81(4):111-4. PubMed ID: 4888811
    [No Abstract]   [Full Text] [Related]  

  • 51. Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1978 Oct; 42(4):1720-9. PubMed ID: 213184
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effect of the hormonal treatment of prostate cancer on the hemostasis system].
    Chekalina SI; Dunchik VN; Sviridova TV
    Urol Nefrol (Mosk); 1981; (1):36-8. PubMed ID: 7210361
    [No Abstract]   [Full Text] [Related]  

  • 53. [Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
    Castillo Cádiz O; Martínez Sanz P
    Rev Med Chil; 1985 Apr; 113(4):309-11. PubMed ID: 3835638
    [No Abstract]   [Full Text] [Related]  

  • 54. [Myelopoietic effect of medroxyprogesterone acetate at high parenteral doses in the cancer patient].
    Gustavo Gercovich F; Morgenfeld E; Dragosky M; Murro H; Sorrentino M; Presman A; Martínez RE
    Sangre (Barc); 1982; 27(5):883-90. PubMed ID: 7167850
    [No Abstract]   [Full Text] [Related]  

  • 55. [Rate of survival in prostatic cancer with bone metastasis].
    Kuntz D; Ryckewaert A
    Rev Fr Etud Clin Biol; 1969; 14(6):609-13. PubMed ID: 5824263
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of advanced cancers of the cervix with medroxprogesterone].
    Van Exter C; Pauls F
    J Gynecol Obstet Biol Reprod (Paris); 1972; 1(5 Suppl 2):383-4. PubMed ID: 4681554
    [No Abstract]   [Full Text] [Related]  

  • 57. Optimal management of prostatic cancer.
    Albertsen P; Marshall F
    Geriatrics; 1982 Dec; 37(12):69-72, 77-9. PubMed ID: 7141229
    [No Abstract]   [Full Text] [Related]  

  • 58. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
    Matveev BP; Bukharkin BV; Zhumagazin ZhD
    Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer].
    Morote Robles J; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
    Actas Urol Esp; 1992 Jun; 16(6):451-4. PubMed ID: 1509913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of the carcinoma of the prostate with gestagens (author's transl)].
    Popelier G
    Urologe A; 1973 May; 12(3):134-9. PubMed ID: 4127418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.